Scarica l'app Stockscreener
7.31
5.19%
-0.40
Dopo l'orario di chiusura:
7.33
0.02
+0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLDB Giù?
Forum
Previsione
Frazionamento azionario
Solid Biosciences Inc Borsa (SLDB) Ultime notizie
Friedreich Ataxia research spotlight as Solid Biosciences advances SGT-212 clinical trials - Traders Union
Options Flow: What analysts say about Solid Biosciences Inc stockExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn
Solid Biosciences reports interim data from Duchenne gene therapy trial - Investing.com Australia
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start (NASDAQ:SLDB) - Seeking Alpha
Solid Biosciences says interim results reinforce confidence in SGT-003 potential - Yahoo Finance
SLDB: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Truist reiterates Buy on Solid Biosciences stock after trial data - Investing.com
Solid Biosciences (SLDB): Chardan Capital Maintains Buy Rating w - GuruFocus
Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data - TipRanks
Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga
Solid Biosciences (SLDB) Shares Drop After New Trial Data Releas - GuruFocus
Solid Biosciences reports interim data from Duchenne gene therapy trial By Investing.com - Investing.com Nigeria
Solid Biosciences (NASDAQ:SLDB) Shares Down 6.3%Time to Sell? - MarketBeat
Solid Biosciences shares fall after gene therapy trial data - Investing.com
Solid Bio falls amid new data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences shares fall after gene therapy trial data By Investing.com - Investing.com Canada
Solid Biosciences (SLDB) Reveals Encouraging Interim Data from S - GuruFocus
Solid Biosciences Inc. unveils positive interim data from Duchenne gene therapy trial - Traders Union
Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial - TradingView
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - Yahoo Finance
Wedbush Reiterates Outperform Rating for SLDB with $14 Price Tar - GuruFocus
Wedbush Reaffirms "Outperform" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Big Money Moves: Will Solid Biosciences Inc stock recover after earnings2026 Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Bain Capital Life Sciences (SLDB) caps Solid Biosciences stake at 9.99% after PIPE - Stock Titan
RA Capital details 9.9% Solid Biosciences (SLDB) ownership position - Stock Titan
Barclays Maintains Solid Biosciences (SLDB) Overweight Recommendation - MSN
Solid Biosciences Secures $240 Million in Private Placement - Global Legal Chronicle
Solid Biosciences (NASDAQ:SLDB) Reaches New 1-Year HighShould You Buy? - MarketBeat
Solid Biosciences secures $240M private placement funding By Investing.com - Investing.com Canada
Solid Biosciences Announces $240 Million Private Placement Financing - TipRanks
Solid Biosciences Raises $240 Million in Private Placement of Stock and Pre-Funded Warrants - TradingView
Solid Biosciences Inc. announced that it expects to receive $239.972139 million in funding - marketscreener.com
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Bitget
Solid Biosciences (SLDB) Announces $240M Private Placement - GuruFocus
Solid Biosciences Announces Oversubscribed $240 Million Private Placement - Bitget
Solid Biosciences announces $240 million private placement - MSN
Solid Biosciences secures $240M private placement funding - Investing.com India
Solid Biosciences Commences $240 Million Private Placement of Common Shares, Pre-Funded Warrants - marketscreener.com
Solid Biosciences stock jumps on $240M private placement - Investing.com
Solid Biosciences stock jumps on $240M private placement By Investing.com - Investing.com Nigeria
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
SLDB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Solid Biosciences (SLDB) Stock Price, News & Analysis - MarketBeat
Biotech Sector Sustains After-Hours Trading Gains - Intellectia AI
Solid Biosciences (SLDB) Projected to Post Earnings on Thursday - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences Inc. sponsors international muscular dystrophy conference in Rome - Traders Union
SLDB SEC FilingsSolid Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Solid Biosciences CTO Herzich sells $21k in shares By Investing.com - Investing.com South Africa
Solid Biosciences CEO Cumbo sells $96k in shares By Investing.com - Investing.com Canada
Solid Biosciences CTO Herzich sells $21k in shares - Investing.com India
Solid Biosciences COO Howton sells $43k in shares - Investing.com Australia
Patterns Watch: What are Solid Biosciences Incs earnings expectationsMarket Activity Recap & Safe Entry Trade Signal Reports - baoquankhu1.vn
David Howton Sells 7,469 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells $96,868.08 in Stock - MarketBeat
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):